Calcineurin Inhibitors and COVID-19

Reumatol Clin (Engl Ed). 2022 May;18(5):314-315. doi: 10.1016/j.reumae.2020.09.007.

Authors

René Hage¹, Macé M Schuurmans²

Affiliations

¹ University Hospital Zurich, Division of Pulmonology, Raemistrasse 100, 8091 Zurich, Switzerland; University of Zurich, Faculty of Medicine, Raemistrasse 71, 8006 Zurich, Switzerland. Electronic address: rene.hage@usz.ch.
² University Hospital Zurich, Division of Pulmonology, Raemistrasse 100, 8091 Zurich, Switzerland; University of Zurich, Faculty of Medicine, Raemistrasse 71, 8006 Zurich, Switzerland.

No abstract available

Publication types

Letter
Comment

MeSH terms

COVID-19*
Calcineurin Inhibitors* / pharmacology
Calcineurin Inhibitors* / therapeutic use
Humans
Immunosuppressive Agents / adverse effects

Substances

Calcineurin Inhibitors
Immunosuppressive Agents